Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints ...

announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp.